Benefits
Lactose digestion improvement
S. thermophilus produces β-galactosidase, the enzyme that hydrolyzes lactose. A distinguishing mechanism — most probiotics don't directly digest lactose. Demonstrates measurable improvement in lactose digestion in lactose-maldigesting subjects.
Antibiotic-associated diarrhea prevention
In one randomized trial (Correa 2005), a B. lactis plus S. thermophilus formula given to 157 infants aged 6 to 36 months starting antibiotics reduced antibiotic-associated diarrhea from 31 percent of controls to 16 percent over 15 days (RR about 0.52). This is combination evidence: the individual S. thermophilus contribution cannot be isolated.
ST36 immune + intestinal function support
An 8-week trial in adults aged 18 to 45 (NCT06779994, Wecare Probiotics) tested the ST36 strain for immune and intestinal function. The trial is listed as completed but has not been published, so its results are not available and this is not yet evidence of a benefit.
Studied only as part of the VSL#3 8-strain blend
S. thermophilus is one of eight strains in the VSL#3 probiotic, which has been studied as an add-on in ulcerative colitis, a disease. That evidence is for the 8-strain combination, not for S. thermophilus taken alone.
Postbiotic anti-inflammatory peptides
In laboratory studies, postbiotic (non-viable) preparations from certain S. thermophilus strains changed IL-1 beta levels in cultured macrophages. This is in-vitro work only, with no human outcome measured.
Folic acid (B9 vitamin) production
S. thermophilus can synthesize folate during dairy fermentation, which is uncommon among probiotics and can raise the folate content of some fermented products. No human trial has shown that taking it changes a person's folate status, so this is a fermentation property rather than a measured health benefit.
Exopolysaccharide (EPS) production
S. thermophilus produces exopolysaccharides that give fermented dairy its texture. Effects on the human gut barrier and immune function come from laboratory and animal work, not from human trials of this strain, so this is a mechanism rather than a measured health benefit.
Mechanism of action
β-galactosidase (lactose digestion)
Foundational mechanism: S. thermophilus secretes β-galactosidase that hydrolyzes lactose into glucose and galactose. Direct enzymatic mechanism — distinguishing from indirect probiotic effects.
Exopolysaccharide (EPS) immunomodulation
EPS production supports gut barrier function, immunomodulation, and yogurt texture. Also contributes to colonization persistence in the gut environment.
Folic acid (B9 vitamin) biosynthesis
S. thermophilus synthesizes folate de novo — rare among probiotics. Direct B9 vitamin production during fermentation enhances the nutritional value of yogurt and may contribute to gut folate status.
Short-chain fatty acid (SCFA) fermentation
Carbohydrate fermentation produces short-chain fatty acids (acetate, lactate) that fuel colonocytes and support gut barrier function. Standard probiotic SCFA mechanism.
Postbiotic intracellular protein bioactivity
PMC11013757 mechanism — intracellular proteins hydrolyzed to peptides with anti-inflammatory bioactivity (IL-1β modulation in THP-1 macrophages). The non-viable cells and their components carry distinct bioactivity beyond live cell action.
Antibacterial + competitive exclusion
Acid production and competitive niche occupation suppress pathogen overgrowth. Standard probiotic antimicrobial mechanism.
GRAS by FDA + QPS by EFSA regulatory recognition
Generally Recognized As Safe (FDA) + Qualified Presumption of Safety (EFSA) — regulatory recognition reflecting decades of safe yogurt and dairy use. Provides a regulatory safety baseline that most probiotic species don't have.
Clinical trials
169-inpatient clinical trial in children 6-36 months on antibiotics.
157 infants aged 6 to 36 months starting antibiotics (80 on the B. lactis plus S. thermophilus formula, 77 controls).
Randomized formula-controlled trial (Correa 2005) in 157 infants aged 6 to 36 months starting antibiotics: a B. lactis plus S. thermophilus formula versus control formula for 15 days. Antibiotic-associated diarrhea occurred in 16 percent of the probiotic group versus 31 percent of controls (RR about 0.52). This is combination evidence; the S. thermophilus contribution cannot be isolated.
NCT02518295 Nestlé β-galactosidase lactose digestion crossover clinical trial.
41 lactose-maldigesting adults in a crossover trial (NCT02518295, completed but unpublished).
NCT02518295, a Nestlé crossover trial in 41 lactose-maldigesting adults testing S. thermophilus and B. longum arms against controls. The trial is completed but unpublished, so its results are not available in the peer-reviewed literature and no lactose-digestion effect for this strain can be confirmed from it.
NCT06779994 ST36 8-week immune + intestinal function clinical trial in adults 18-45 (Wecare Probiotics).
98 adults aged 18 to 45 (NCT06779994, completed but unpublished).
NCT06779994, an 8-week trial in 98 adults aged 18 to 45 (Wecare Probiotics) of the ST36 strain for immune and intestinal function. Listed as completed but not published, so no results are available and this does not yet support a benefit.